Charles Russell Speechlys advises Kreos and SVB on refinancing of £20 million growth capital investment to Mereo BioPharma
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited and Silicon Valley Bank on the refinancing of their £20 million growth capital investment to Mereo BioPharma Group plc (“Mereo BioPharma”), a clinical stage UK-based biopharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma focuses on the development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies.
The Charles Russell Speechlys core team comprised Rossana Conti (Legal Director), Amelly Kok (Associate) and Charlie Searle (Corporate Trainee) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking & Finance Team.
News & Insights
Urban Air Aviation: is your building
The drone revolution is not something for the future, it is something that is already underway.
Charles Russell Speechlys advises discoverIE Group plc on its acquisition of Sens-Tech Limited
Charles Russell Speechlys advised long standing client, discoverIE on its acquisition of Xi-Tech Ltd and its subsidiary Sens-Tech Ltd.
SMCR – Briefing Note for Broking and Trading Firms
All broking and trading firms which are regulated by the FCA will become subject to the SMCR on 9 December 2019.
The value of Simone Biles – an update on athlete endorsements, the Olympics and Rule 40
the USOPC released updated guidance for its athletes regarding personal endorsements and marketing during the Tokyo 2020 games.